The American Society of Plastic Surgeons (ASPS) has released its 2025 Procedural Statistics Report. The report highlights changing patient preferences across cosmetic surgery and minimally invasive aesthetic treatments.
Cosmetic surgical procedures increased 7 per cent in 2025 compared with the previous year. The findings point to growing interest in restoration, skin quality and age-related aesthetic care. Patients increasingly sought treatments that restore volume and support natural-looking outcomes.
Injectables continue to lead minimally invasive procedures
Neuromodulators remained the most performed minimally invasive treatment category in 2025. They accounted for 50 per cent of all minimally invasive procedures tracked by ASPS.
Hyaluronic acid fillers represented another 30 per cent of minimally invasive procedures. Together, neuromodulators and HA fillers accounted for 80 per cent of minimally invasive treatments.
The figures reinforce the continued importance of injectables within the broader aesthetic medicine market. Medical spas may also see continued demand for treatments focused on facial rejuvenation and skin quality.
Also read: Classys partners with Photonence to expand in India
Volume restoration gains momentum
ASPS reported a 39 per cent increase in facial fat grafting procedures during 2025. This represented the largest year-over-year increase among the tracked procedures.
The growth reflects stronger interest in restoring facial volume following ageing and other changes. Fat grafting remains a surgical procedure, but the trend extends beyond surgical aesthetics.
Patients also continue seeking minimally invasive options that address volume loss and facial ageing. These include dermal fillers and other treatments designed to improve facial volume. The findings suggest that restoration remains an important consideration across aesthetic treatment plans.
GLP-1 use influences aesthetic consultations
The report also highlights the growing relevance of GLP-1 medications within aesthetic practices. According to ASPS, 82 per cent of member surgeons received consultations related to GLP-1 use.
The report does not establish a direct link between GLP-1 use and procedure increases. However, surgeons reported growing interest in concerns following significant weight loss.
Patients sought advice about skin laxity, volume loss and excess skin after weight reduction. This trend could influence treatment planning across surgical and non-surgical aesthetic practices. Medical spas may encounter more patients seeking skin rejuvenation and body contouring after weight loss.
Older patients drive procedure growth
Older adults also recorded significant growth in cosmetic procedure volumes during 2025. Patients aged 66 and above recorded a 24 per cent increase in cosmetic procedure volume. This represented the fastest growth among the reported age groups.
Meanwhile, procedure volume declined among patients younger than 36. Adults aged 36 to 55 still accounted for nearly half of all cosmetic procedures. The figures indicate continued demand from consumers seeking aesthetic care later in life. Healthy ageing therefore remains an important theme for aesthetic practices.
Skin treatments remain important
Energy-based and skin rejuvenation treatments also maintained a strong position within the market. Laser skin treatments remained among the leading minimally invasive procedures tracked by ASPS. The report also identified IPL, hair removal and tattoo removal among commonly performed treatments. These findings highlight continued consumer interest in improving skin quality and appearance.
For aesthetic practices, treatment demand continues to span injectables, devices and restorative procedures. The 2025 statistics show an aesthetic market shaped by restoration and personalised treatment goals. Patients increasingly seek approaches that complement their appearance rather than dramatically change it.
For medical spas and aesthetic providers, these trends could shape treatment planning through 2026. The ASPS findings highlight continued demand for injectables, volume restoration and healthy-ageing services.